Innovative therapies in the treatment of keloids and hypertrophic scars

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 5, 2010, Pages

  Viera, Martha H ^a   Amini, Sadegh ^a   Valins, Whitney ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BOTULINUM TOXIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; DIPHENHYDRAMINE; IMIQUIMOD; INTERLEUKIN 10; ISOTRETINOIN; MANNOSE 6 PHOSPHATE; METHOTREXATE; MITOMYCIN C; PHENIRAMINE MALEATE; PROSTAGLANDIN E2; QUINOLINE DERIVATIVE; RAPAMYCIN; RESIQUIMOD; RETINOID DERIVATIVE; SCATTER FACTOR; SILICONE; SMALL INTERFERING RNA; TACROLIMUS; TAMOXIFEN CITRATE; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ATOPIC DERMATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; FOLLICULITIS; HUMAN; HYPERTROPHIC SCAR; KELOID; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATIENT SATISFACTION; REVIEW; SCAR; SINGLE DRUG DOSE; TREATMENT OUTCOME; WOUND HEALING;

EID: 77954266939     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Lee DA. Antifibrosis agents and glaucoma surgery. Invest Ophthalmol Vis Sci. 1994;35:3789-3791.
2. Stewart CE IV, Kim JY. Application of mitomycin-C for head and neck keloids. Otolaryngol Head Neck Surg. 2006;135:946-950.
3. Bailey JN, Waite AE, Clayton WJ, et al. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. Br J Dermatol. 2007;156:682-686.
4. Stewart CE IV, Kim JY. Application of mitomycin-C for head and neck keloids. Otolaryngol Head Neck Surg. 2006;135:946-950.
5. Talmi YP, Orenstein A, Wolf M, Kronenberg J. Use of mitomycin C for treatment of keloid: A preliminary report. Otolaryngol Head Neck Surg. 2005;132:598-601.
6. Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg. 2005;7:172-175.
7. Simman R, Alani H, Williams F. Effect of mitomycin C on keloid fibroblasts: an in vitro study. Ann Plast Surg. 2003;50:71-76.
8. Gragnani A, Warde M, Furtado F, Ferreira LM. Topical tamoxifen therapy in hypertrophic scars or keloids in burns. Arch Dermatol Res. 2010;302(1):1-4. Epub 2009 Jul 28.
9. Mancoll JS, Zhao J, McCauley RL, Phillips LG. The inhibitory effect of tamoxifen on keloid fibroblasts. Surg Forum. 1996;47:718-720.
10. Hu D, Hughes MA, Cherry GW. Topical tamoxifen-a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg. 1998;51(6):462-469.
11. Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg. 2001;3(2):111-114.
12. Chau D, Mancoll JS, Lee S, et al. Tamoxifen downregulates TGF-beta production in keloid fibroblasts. Ann Plast Surg. 1998;40(5):490-493.
13. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum. 1998;41:381-391.
14. Onwukwe MF. Treating keloids by surgery and methotrexate. Arch Dermatol. 1980;116:158.
15. Sauder DN, Smith MH, Senta-McMillian T, Soria I, Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother. 2003;47:3846-3852.
16. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest. 1984;74:1112-1116.
17. Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res. 1995;28:253-264.
18. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. 2002;47:S209-S211.
19. Martin-Garcia RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg. 2005;31:1394-1398.
20. Stashower ME. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. Dermatol Surg. 2006;32:380-386.
21. Jacob S.E, Berman B, Nassiri M, Vincek V. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol. 2003;149 Suppl 66:62-65.
22. Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg. 2009;35(4):629-633.
23. Daly TJ, Weston WL. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol. 1986;15:900-902.
24. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, Uitto J. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol. 1985;121:632-635.
25. Oikarinen H, Oikarinen AI, Tan EM, et al. Modulation of procollagen gene expression by retinoids. Inhibition of collagen production by retinoic acid accompanied by reduced type I procollagen messenger ribonucleic acid levels in human skin fibroblast cultures. J Clin Invest. 1985;75:1545-1553.
26. Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg. 1994;33(4):401-405.
27. Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol. 1988;14:1275-1276.
28. Hansen DA. Treatment of hypertrophic scars with retinoic acid. S Afr Med J. 1979;56:1114.
29. Janssen de Limpens AM. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol. 1980;103:319-323.
30. Goh MS, Magee J, Chong AH. Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae. Australas J Dermatol. 2005;46(4):257-260.
31. Berman B, Amini S, Viera M. Keloid and hypertrophic scar. WebMD Health Professional Network. www.emedicine.com. Accessed February 18, 2010.
32. Ong CT, Khoo YT, Mukhopadhyay A, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. 2007;16:394-404.
33. Kim A, DiCarlo J, Cohen C, et al. Are keloids really "gli-loids"? High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol. 2001;45:707-711.
34. Ong CT, Khoo YT, Tan EK, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol. 2007;211:95-108.
35. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80(3):253-360.
36. Berman B, Villa A, Ramirez C. Novel opportunities in the treatment and prevention of scarring. J Cutan Med Surg. 2005;8(3):32-36.
37. D'Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology. 2002;204(1):60-62.
38. Skaria AM. Prevention and treatment of keloids with intralesional verapamil. Dermatology. 2004;209(1):71.
39. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg. 1996;37(2):167-169.
40. Zhibo X, Miaobo Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg. 2008;61(9):1128-1129. Epub 2008 Jun 13.
41. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. 2009;124(5):275e-277e.
42. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33(3):409-412. Epub 2009 Apr 9.
43. Venus M.R. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2007;119(1):423-424; author reply 424.
44. Salem A, Assaf M, Helmy A, et al. Role of vascular endothelial growth factor in keloids: a clinicopathologic study. Int J Dermatol. 2009;48(10):1071-1077.
45. Tiscornia G, Singer O, Ikawa M, et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A. 2003;100(4):1844-1848.
46. Gira AK, Brown LF, Washington CV, et al. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol. 2004; 50(6):850-853.
47. Steinbrech DS, Mehrara BJ, Chau D, et al. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. 1999;42(5):514-519; discussion 519-520c.
48. Le AD, Zhang Q, Wu Y, et al. Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis. Cells Tissues Organs. 2004;176(1-3):87-94.
49. Zhang GY, Yi CG, Li X, et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res. 2008;300(4):177-184.
50. Tiede S, Ernst N, Bayat A, et al. Basic fibroblast growth factor: a potential new therapeutic tool for the treatment of hypertrophic and keloid scars. Ann Anat. 2009;191(1):33-44.
51. Xie JL, Bian HN, Qi SH, et al. Basic fibroblast growth factor (bFGF) alleviates the scar of the rabbit ear model in wound healing. Wound Repair Regen. 2008;16(4):576-581.
52. Ono I, Akasaka Y, Kikuchi R, et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds. Wound Repair Regen. 2007;15(5):617-623.
53. Naim R, Naumann A, Barnes J, et al. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. Aesthetic Plast Surg. 2008;32(2):346-352.
54. Ono I, Yamashita T, Hida T, et al. Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J Surg Res. 2004;120(1):47-55.
55. Viera MH, Amini S, Konda S, Berman B. Do postsurgical interventions optimize ultimate scar cosmesis. G Ital Dermatol Venereol. 2009;144(3):243-257.
56. A double blind, placebo controlled trial to investigate the efficacy and safety of two concentrations of juvidex (Mannose-6-Phosphate) in accelerating the healing of split thickness skin graft donor sites using different dosing regimes. ClinicalTrials.gov Identifier: NCT00664352. http://clinicaltrials.gov/NCT00664352. Accessed February 18, 2010.
57. Liechty KW, Kim HB, Adzick NS, et al. Fetal wound repair results in scar formation in interleukin-10-defcient mice in a syngeneic murine model of scarless fetal wound repair. J Pediatr Surg. 2000;35:866-872;discussion 872-863.
58. Peranteau WH, Zhang L, Muvarak N, et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol. 2008;128(7):1852-1860.
59. A single-centre, placebo and standard-care-controlled, double-blind, randomised trial to investigate the efficacy of eight doses of RN1003 in the reduction of scarring from the approximated wound margins of incisional wounds. ClinicalTrials.gov Identifier: NCT00984646. http://clinicaltrials.gov/NCT00664352. Accessed February 18, 2010.
60. Liu W, Wang DR, Cao YL. TGF-beta: a fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. Curr Gene Ther. 2004;4(1):123-136.
61. Gao Z, Wang Z, Shi Y, et al. Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. Plast Reconstr Surg. 2006;118(6):1328-1337.
62. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1(3):169-178.
63. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370(6488):341-347.
64. Meier K, Nanney LB. Emerging new drugs for scar reduction. Expert Opin Emerg Drugs. 2006;11(1):39-47.
65. Ferguson MW, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet. 2009;373(9671):1264-1274.
66. A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars. ClinicalTrials.gov Identifier: NCT00742443. http://www.clinicaltrials.gov/ct2/show/NCT00742443. Accessed February 16, 2010.
67. Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003;10(1):59-71.
68. Choi BM, Kwak HJ, Jun CD, et al. Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides. Immunol Cell Biol. 1996;74(2):144-150.
69. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet. 1992;339(8787):213-214.
70. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107 (Pt 5):1137-1157.
71. Robson MC. Proliferative scarring. Surg Clin North Am. 2003;83(3):557-569.
72. Schonherr E, Broszat M, Brandan E, et al. Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch Biochem Biophys. 1998;355(2):241-248.
73. Zhao J, Sime PJ, Bringas P Jr, et al. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol. 1999;277(2 Pt 1):L412-L422.
74. Abdel-Wahab N, Wicks SJ, Mason RM, Chantry A. Decorin suppresses transforming growth factor-beta-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca2+-dependent phosphorylation of Smad2 at serine-240. Biochem J. 2002;362(Pt 3):643-649. Erratum in: Biochem J. 2002;366(Pt 3):999.
75. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol. 2001;280(6):L1327-L1334.
76. Runyan CE, Schnaper HW, Poncelet AC. The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells. J Biol Chem. 2005;280(9):8300-8308.
77. Zhao BM, Hoffmann FM. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell. 2006;17(9):3819-3831.
78. Faresse N, Colland F, Ferrand N, et al. Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling. EMBO J. 2008;27(13):1804-1815.
79. Liu F. PCTA: a new player in TGF-beta signaling. Sci Signal. 2008;1(46):pe49.
80. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107(2):179-185.
81. Miyazawa K, Hamano S, Ujiie A. Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Br J Pharmacol. 1996;118(4):915-922.
82. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992:60(2):91-96.
83. Topol BM, Lewis VL Jr, Benveniste K. The use of antihistamine to retard the growth of fibroblasts derived from human skin, scar, and keloid. Plast Reconstr Surg. 1981;68(2):227-232.
84. Venugopal J, Ramakrishnan M, Habibullah CM, Babu M. The effect of the anti-allergic agent avil on abnormal scar fibroblasts. Burns. 1999;25(3):223-228.
85. Shigeki S, Murakami T, Yata N, Ikuta Y. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg. 1997:31(2):151-158.
86. Yamada H, Tajima S, Nishikawa T, et al. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo). 1994;116(4):892-897.
87. Kampfer H, Brautigam L, Geisslinger G, et al. Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol. 2003;120(5):880-890.
88. Muller-Decker K, Hirschner W, Marks F, Furstenberger G. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J Invest Dermatol. 2002;119(5):1189-1195.
89. Talwar M, Moyana TN, Bharadwaj B, Tan LK. The effect of a synthetic analogue of prostaglandin E2 on wound healing in rats. Ann Clin Lab Sci. 1996;26(5):451-457.
90. Lundberg C, Gerdin B. The inflammatory reaction in an experimental model of open wounds in the rat. The effect of arachidonic acid metabolites. Eur J Pharmacol. 1984;97(3-4):229-238.
91. Wilgus TA, Bergdall VK, Tober et al. The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing. Am J Pathol. 2004;165(3):753-761.
92. Bitterman PB, Wewers MD, Rennard SI, Adelberg S, Crystal RG. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest. 1986;77(3):700-708.
93. Lama V, Moore BB, Christensen P, et al. Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol. 2002;27(6):752-758.
94. Sandulache VC, Parekh A, Li-Korotky H, et al. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. 2007;15(1):122-133.
95. Varga J, Diaz-Perez A, Rosenbloom J, Jimenez SA. PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts. Biochem Biophys Res Commun. 1987;147(3):1282-1288.
96. Riquet FB, Lai WF, Birkhead JR, et al. Suppression of type I collagen gene expression by prostaglandins in fibroblasts is mediated at the transcriptional level. Mol Med. 2000;6(8):705-719.
97. Yeh FL, Shen HD, Lin MW, et al. Keloid-derived fibroblasts have a diminished capacity to produce prostaglandin E2. Burns. 2006;32(3):299-304
98. Hayashi T, Nishihira J, Koyama Y, et al. Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. J Invest Dermatol. 2006;126(5):990-997.